Edgewise Therapeutics(EWTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Completed Phase 1 SAD and MAD trial of EDG-7500 in healthy volunteers; Dosing patients in Phase 2 CIRRUS-HCM trial of EDG-7500 in individuals with oHCM – – Continued to advance GRAND CANYON global pivotal cohort of sevasemten in adults with Becker – – Advanced Phase 2 LYNX and FOX trials of sevasemten in children with Duchenne – Boulder, Colo., (August 8, 2024) – Edgewise Therapeuti ...